Fibroblast growth factor-23 in patients with graves' disease before and after antithyroid therapy: Its important role in serum phosphate regulation

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 7, 2005, Pages 4211-4215

  Yamashita, Hiroyuki ^a,g   Yamazaki, Yuji ^b   Hasegawa, Hisashi ^b   Yamashita, Takeyoshi ^b   Fukumoto, Seiji ^c   Shigematsu, Takashi ^d   Kazama, Junichiro James ^e   Fukagawa, Masafumi ^f   Noguchi, Shiro ^a  

^a Noguchi Thyroid Clinic and Hospital Foundation   (Japan)

^b KIRIN BREWERY CO LTD   (Japan)

^c UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^d Jikei University School of Medicine   (Japan)

^e NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^f KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g Noguchi Thyroid Clin/Hosp Found   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; CALCITRIOL; CALCIUM; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE; THIAMAZOLE;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GRAVES DISEASE; HOMEOSTASIS; HUMAN; HYPERPHOSPHATEMIA; HYPERTHYROIDISM; HYPOPHOSPHATEMIA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PATIENT; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; VITAMIN BLOOD LEVEL;

ADULT; AGED; ANTITHYROID AGENTS; CALCIUM; CROSS-SECTIONAL STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; GRAVES DISEASE; HUMANS; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHATES;

EID: 23044460989     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-2498     Document Type: Article

References (29)

1. Quarles LD, Drezner MK 2001 Pathophysiology of X-linked hypophosphatemia, tumor-induced osteomalacia, and autosomal dominant hypophosphatemia: a perPHEXing problem. J Clin Endocrinol Metab 86:494-496
2. Weber TJ, Liu S, Indridason OS, Quarles LD 2003 Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 18:1227-1234
3. The ADHR Consortium 2000 Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345-348.
4. Cai Q, Hodgson SF, Kao PC, Lennon VA, Klee GG, Zinsmiester AR, Kumar R 1994 Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med 330:1645-1649
5. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2001 Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500-6505
6. Fukumoto S, Yamashita T 2002 Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin. Curr Opin Nephrol Hypertens 11:385-389
7. Larsson T, Zahradnik R, Lavigne J, Ljunggren O, Juppner H, Jonsson KB 2003 Immunohistochemical detection of FGF-23 protein in tumors that cause oncogenic osteomalacia. Eur J Endocrinol 148:269-276
8. Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, Yoneya T, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2004 FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 314:409-414
9. Farnsworth AE, Dobyns BM 1974 Hypercalcaemia and thyrotoxicosis. Med J Aust 2:782-784
10. Langdahl BL, Loft AG, Eriksen EF, Mosekilde L, Charles P 1996 Bone mass, bone turnover, body composition, and calcium homeostasis in former hyperthyroid patients treated by combined medical therapy. Thyroid 6:161-168
11. Mosekilde L, Melsen F 1978 Effect of antithyroid treatment on calcium-phosphorus metabolism in hyperthyroidism. II. Bone histomorphometry. Acta Endocrinol (Copenh) 87:751-758
12. Mosekilde L, Melsen F, Bagger JP, Myhre-Jensen O, Schwartz Sorensen N 1977 Bone changes in hyperthyroidism: interrelationships between bone morphometry, thyroid function and calcium-phosphorus metabolism. Acta Endocrinol (Copenh) 85:515-525
13. Cleeve HJ, Brown IR 1978 Plasma 25-hydroxyvitamin D and alkaline phosphatase isoenzymes in hyperthyroidism. Ann Clin Biochem 15:320-323
14. Iqbal AA, Burgess EH, Gallina DL, Nanes MS, Cook CB 2003 Hypercalcemia in hyperthyroidism: patterns of serum calcium, parathyroid hormone, and 1,25-dihydroxyvitamin D3 levels during management of thyrotoxicosis. Endocr Pract 9:517-521
15. Barsal G, Taneli F, Atay A, Hekimsoy Z, Erciyas F 2004 Serum osteocalcin levels in hyperthyroidism before and after antithyroid therapy. Tohoku J Exp Med 203:183-188
16. Reinhardt TA, Horst RL, Orf JW, Hollis BW 1984 A microassay for 1,25-dihydroxyvitamin D not requiring high performance liquid chromatography: application to clinical studies. J Clin Endocrinol Metab 58:91-98
17. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S 2002 Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957-4960
18. Yamashita H, Yamashita T, Miyamoto M, Shigematsu T, Kazama JJ, Shimada T, Yamazaki Y, Fukumoto S, Fukagaw M, Noguchi S 2004 Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism. Eur J Endocrinol 151:55-60
19. Mundy GR, Shapiro JL, Bandelin JG, Canalis EM, Raisz LG 1976 Direct stimulation of bone resorption by thyroid hormones. J Clin Invest 58:529-534
20. Sorribas V, Markovich D, Verri T, Biber J, Murer H 1995 Thyroid hormone stimulation of Na/Pi-cotransport in opossum kidney cells. Pflugers Arch 431:266-271
21. Castro JH, Genuth SM, Klein L 1975 Comparative response to parathyroid hormone in hyperthyroidism and hypothyroidism. Metabolism 24:839-848
22. Jastrup B, Mosekilde L, Melsen F, Lund B, Lund B, Sorensen OH 1982 Serum levels of vitamin D metabolites and bone remodelling in hyperthyroidism. Metabolism 31:126-132
23. Gupta A, Winer K, Econs MJ, Marx SJ, Collins MT 2004 FGF-23 is elevated by chronic hyperphosphatemia. J Clin Endocrinol Metab 89:4489-4492
24. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB 2003 Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64:2272-2279
25. Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi A, Kobayashi K, Miki T, Shoji T, Ishimura E, Nishizawa Y 2004 FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 65:1943-1946
26. Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, Fukagawa M 2004 Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 44:250-256
27. Sato T, Tominaga Y, Ueki T, Goto N, Matsuoka S, Katayama A, Haba T, Uchida K, Nakanishi S, Kazama JJ, Gejyo F, Yamashita T, Fukagawa M 2004 Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis 44:481-487
28. Yamashita T, Konishi M, Miyake A, Inui K, Itoh N 2002 Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J Biol Chem 277:28265-28270
29. Murer H, Hernando N, Forster I, Biber J 2000 Proximal tubular phosphate reabsorption: molecular mechanisms. Physiol Rev 80:1373-1409